Surrogate Decision Makers Wish To Retain Authority In Decision To Stop Life-Support For Incapacitated And Critically Ill Patients
(more...)
Amira Pharmaceuticals, Inc. announced today that it has initiated a Phase 1 clinical study with AM152, a novel LPA1 antagonist, in normal, healthy subjects. “We are excited to begin our journey exploring the therapeutic value of AM152, a potentially novel anti-fibrotic agent…